Related Experiment Video

Updated: Jul 2, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Molecular basis of targeted therapy in metastatic renal cancer]

H Moch1

  • 1Institut für Klinische Pathologie, Departement Pathologie, Universitätsspital Zürich, Schmelzbergstr. 12, 8091 Zürich. holger.moch@usz.ch

Der Pathologe
|August 30, 2008
PubMed

Insights

Targeted therapies for metastatic renal cancer, including sunitinib and sorafenib, show promise by inhibiting pro-angiogenic factors like VEGF. Identifying predictive markers for drug response remains crucial for advancing treatment.

Area of Science:

  • Oncology
  • Molecular Genetics
  • Pharmacology

Background:

  • Metastatic renal cancer is often linked to von Hippel-Lindau gene inactivation.
  • This inactivation leads to elevated pro-angiogenic factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).
  • Targeting these specific molecular pathways is a key strategy in treating clear cell renal cell carcinomas.

Purpose of the Study:

  • To review clinical trials of targeted therapies in advanced renal cell carcinoma.
  • To highlight the link between molecular genetics and the development of effective cancer treatments.
  • To discuss the need for predictive markers in personalized cancer therapy.

Main Methods:

  • Review of clinical trials involving sunitinib, sorafenib, and temsirolimus.
  • Analysis of molecular genetics and signaling pathways in renal cell carcinoma.
  • Examination of the rationale for small molecule inhibitors targeting angiogenesis.

Main Results:

  • Targeted therapies offer individualized treatment options for metastatic renal cancer.
  • Sunitinib, sorafenib, and temsirolimus have been investigated in clinical trials for advanced renal cell carcinoma.
  • Understanding tumor molecular pathways informs the development of promising treatments.

Conclusions:

  • Targeted therapies represent a significant advancement in treating advanced renal cell carcinoma.
  • Further research is needed to identify predictive markers for drug response and resistance.
  • Personalized medicine approaches are essential for optimizing patient outcomes in renal cell carcinoma treatment.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...